Delfi Diagnostics, Inc. announced that it will issue 46,434,241 series B preferred shares at issue price of $4.84556 per share for the gross proceeds $224,999,900.81996 in funding on June 10, 2022. The shares are convertible and non-redeemable. The shares will be convertible in common shares at a fixed conversion price of $4.84556 per share.

The company will issue securities pursuant to exemption provided under Regulation D.